Home » Topics » Regulatory

Regulatory
RSS

FDA clears potent pain reliever without opioid side effects from Wyeth-Ayerst

July 24, 1997

Teva's generic antihypertensive combination tentatively approved

July 23, 1997

U.K. approves Astra's treatment for ulcerative colitis

July 23, 1997

Prograf to be submitted in Japan for atopic dermatitis

July 22, 1997

TAP receives FDA approval to market new formulation of Lupron Depot

July 21, 1997

Rogaine Extra Strength for Men recommended for approval as OTC

July 21, 1997

FDA clears new indication and new labeling for Zoloft

July 18, 1997

Ganciclovir implant effective in treating CMV retinitis

July 17, 1997

RPR launches room-temperature formulation of DDAVP

July 16, 1997

Athena Neurosciences and Wyeth-Ayerst copromote Naprelan

July 16, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...